Rabbit Anti-Human VEGFR-3/FLT-4

Slide this table

Cat-Nr.102-PA22
Size200 µg
Price225 €
CategoryPolyclonal Antibody
Clone Nr.Rabbit IG
Species ReactivityHuman
Formulationlyophilized
BufferPBS
ReconstitutionCentrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1-1.0 mg/ml.
Stability and StorageThe lyophilized antibody is stable at room temperature for up to 1 month. The reconstituted antibody is stable for at least two weeks at 2-8 °C. Frozen aliquots are stable for at least 6 months when stored at -20 °C.
PreparationProduced from sera of rabbits immunised with highly pure recombinant human soluble VEGFR-3/FLT-4 (D1-D7). Anti-human VEGFR-3/FLT-4 was purified by antigen-affinity chromatography with immobilised soluble VEGFR-3/FLT-4.
AntigenRecombinant human sFLT-4 (D1-7) (RT #S01-017)
ApplicationWB, IP, E, IHC (C)
Synonymsvascular endothelial growth factor receptor-3; FLT4; PCL; LMPH1A; VEGFR3; fms-related tyrosine kinase 4
DescriptionReceptor tyrosine Kinase VEGFR-3, also known as FLT4, together with VEGFR1 (FIT1) and VEGFR2 (KDR/Flk-1), are the receptors for vascular endothelial growth factors (VEGF). The VEGFR family belongs to the class II subfamily of receptor tyrosine kinases (RTKs), containing a large extracellular region which is composed of seven Ig-like domains (D1–D7), a single transmembrane (TM) helix and cytoplasmic region with a tyrosine kinase activity. In VEGFR-3, the fifth Ig homology domain is proteolytically cleaved which results in polypeptides remain linked by two disulfide bonds. VEGFR-3 is widely expressed on all endothelia cells in early embryogenesis, while, in adult tissues, VEGFR-3 expression disappears from the vascular endothelial cells and is observed only on the lymphatic endothelium. VEGF-C and VEGF-D activation of VEGFR-3 plays an important role in the formation of the lymphatic vessel system.
Uniprot IDP35916
Protein RefSeqNP_002011
mRNA RefSeqNM_002020

Figures


Reference

  1. Functional Importance of a Proteoglycan Coreceptor in Pathologic Lymphangiogenesis. S. C. Johns et al., Circ Res. 2016 Jul 8; 119(2): 210–221.
  2. The defect of both angiogenesis and lymphangiogenesis is involved in preeclampsia. Liu H et al., Placenta. 2015 Mar;36(3):279-86.
  3. Lymphatic Endothelial Heparan Sulfate Deficiency Results in Altered Growth Responses to Vascular Endothelial Growth Factor-C (VEGF-C). X. Yin et al., J Biol Chem. 2011 Apr 29; 286(17): 14952–14962.

All prices plus VAT + possible delivery charges